Table of Contents Table of Contents i Introduction 1 1 Definition of The Pharmaceutical Industry 1 2 Environmental Analysis 2 2.1 Legal Issues 2 2.2 Political Issues 2 2.3 Economic Issues 2 2.4 Social Issues 2 2.5 Technological Issues 2 3 Forces of Competition 3 4 Value Chain 4 4.1 Discovery 4 4.2 Production Development 4 4.3 Manufacturing 4 4.4 Marketing 4 5 Role of Information Systems & Technology 4 6 GlaxoSmithKline 5 7 United Drug 6 7.1 Company Overview
Premium Pharmaceutical industry Pharmacology Drug discovery
[online]. Available from: http://www.opm.gov/perform/articles/pdf3.asp. [Accessed 31 December 2009]. * Taylor‚ S * Torrington‚ D.‚ Hall‚ L. and Taylor‚ S. (2005) Human resource management. 6th ed. Harlow: FT Prentice Hall. IDS HR Studies (2005) Biogen Idec — IDS HR Studies 796 [online]. Available from: http://www.idshrstudies.com/app/smg/gbn/frameless/document/body?docguid=Iad5e68c13c2e11dc854300123f934565&restype=31
Premium Human resource management Performance management Performance appraisal
XenoMouse: Produces antibodies for disease targets Benefits: Longer therapy‚ fewer side effects‚ faster drug development Abgenix & the Xenomouse 1 Case Questions • Which of the three alternatives would you recommend to the company? 1. A Pharmacol “hand-off” deal (who is Pharmacol)? 2. A Biopart “hand-in” deal (who is Biopart)? 3. “Go-it-alone” through Phase II & then decide a development strategy? • What are the direct financial implications of your answer? • What are the strategic
Premium Clinical trial
Company 38 Individual change 38 Team change 38 Organizational change 39 Leading change 39 Case study 4: Biogen Idec 40 Case study text: Biogen Idec 40 The change 42 Data gathering and option generation 43 Affiliates and culture change 43 Criteria for good change 44 The transition 45 Case study questions: Biogen Idec 46 Individual change 46 Team change 46 Organizational change 47 Leading change 47 Case study 1: Aster Group
Premium Management Public health Change management
The term ‘Biosimilar’ refer to those pharmaceutical products which are biologically similar versions of already existing popular drugs‚ the difference being that biosimilars are produced by a different manufacturer after the expiry of the original drug’s patent and they are more cost-effective than the original drug. The global biosimilar market has grown exponentially over the years due to several factors which include rising medical care costs‚ ageing world population and expensiveness of critical
Premium Clinical trial Growth hormone Pharmacology
References: Biogen Idec Inc. Genentech‚ Inc. (2012). Rituxan and Non Hodgkin’s Lymphoma (NHL). This website is available at www.Rituxan.com. Accessed October 24‚ 2012. National Cancer Institute (2012). NCI website Non Hodgkin’s Lymphoma (NHL).This website is available
Premium Cancer Immune system Blood
Stock Holdings Why we kept these stocks; Focus on FUTURE & what was created or expanded. Compay changes in management or business structure. Etc. Microsoft Many high profile insider investments lead me to believe in the company. Mr. Morfit‚ General Director of Microsoft‚ is stepping up to the plate again and buying more shares on a recent pullback. This leads us to believe he is very pleased with the new CEO and sees big things in the future for this ‘mature tech’ stock. We’re overall very comfortable
Premium Revenue Biogen Idec Stock market
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 BEN&JERRY BERTELSMANN BHARAT GEARS Limited BHARAT Petroleum BHP BILLITON BIC CORPERATION BIG C BIGLOTS BIOGEN IDEC BIOMET BLIZZARD BLUESCOPE STEEL BNP PARIBAS Boconcept BODYSHOP BOEHRINGER INDELHEIM BOEING BOMBARDIER (BBD Inc) BORDERS GROUP.INC BRISTOL-MYERSSQUIBB BRITIISH TELECOM BRITISH AMERICAN TOBACCO BRITISHAIRWAYS BROTHER INDUSTRIES‚ Ltd BROWN - FORMAN
Premium Southwest Airlines Corporation
EPGCMM-06-016 Manager – Corporate Communications Key Account Manager Sales Manager 4. Mr. Marripudi Jaya Rao EPGCMM-06-010 Area Business Manager Organization Sahara India Pariwar Nestle India Ltd Dell India Pvt. Ltd. Biogen Idec India Private and Confidential 1. Looking beyond the immediate Ariba e-Procurement System project‚ what challenging issues related to global marketing does this case pose for Infosys? Ans: The key issue for Infosys here to make a compelling
Premium Costs Investment Christopher Nolan
Daclizumab (Biogen Idec and Abbott Biotherapeutics Corp.) is a humanized mAb acting as a blocker of the α-subunit (CD25) of the high-affinity IL-2 receptor [19]. IL-2 is secreted by activated lymphocytes and stimulates production of other proinflammatory cytokines while it is also involved in lymphocytic proliferation. Daclizumab was initially approved for the prevention of renal allograft rejection as part of a combination regimen and evidence was progressively accumulated showing that this drug
Premium Immune system Cancer Protein